MarketsCamlin Fine Sciences Limited CAMLINFINE
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,323.9 | 2,023.79 | 1,951.72 |
| Cash Equivalents | 153.22 | 35.82 | Not available |
| Other Liabilities Total | 7.76 | 6.05 | 5.78 |
| Long Term Debt | 302.61 | 268.3 | 332.72 |
| Common Stock Total | 19.21 | 18.79 | 16.75 |
| Other Current Assets Total | 148.68 | 60.15 | 19.38 |
| Total Assets | 2,323.9 | 2,023.79 | 1,951.72 |
| Current Portof LT Debt/Capital Leases | 383.08 | 116.86 | 99.69 |
| Total Equity | 1,040.88 | 901.67 | 864.75 |
| Long Term Investments | 48.62 | 25.13 | 7.88 |
| Retained Earnings(Accumulated Deficit) | 1,021.67 | 130.55 | 259.58 |
| Total Common Shares Outstanding | 19.21 | 18.79 | 17.14 |
| Tangible Book Valueper Share Common Eq | 40.53 | 44.91 | 46.96 |
| Goodwill Net | 233.41 | 47.47 | 47.08 |
| Total Liabilities | 1,283.02 | 1,122.11 | 1,086.97 |
| Total Debt | 720.09 | 681.3 | 683.03 |
| Short Term Investments | 57.83 | 39.27 | 0.97 |
| Cashand Short Term Investments | 211.05 | 143.34 | 81.23 |
| Total Receivables Net | 373.02 | 422.06 | 365.56 |
| Deferred Income Tax | 3.91 | 3.31 | 6.84 |
| Accounts Receivable-Trade Net | 373.02 | 328.22 | 285.15 |
| Property/Plant/Equipment Total-Net | 657.94 | 653.63 | 802.33 |
| Minority Interest | -40.07 | -26.89 | -7.8 |
| Total Current Liabilities | 974.42 | 846.21 | 732.27 |
| Total Inventory | 503.74 | 543.34 | 526.23 |
| Accounts Payable | 505.19 | 377.22 | 324.64 |
| Other Currentliabilities Total | 86.14 | 70.05 | 64.9 |
| Total Long Term Debt | 337.01 | 293.44 | 349.88 |
| Intangibles Net | 28.87 | 10.23 | 12.81 |
| Other Long Term Assets Total | 93.41 | 98.7 | 76.12 |
| Note Receivable-Long Term | 25.16 | 5.24 | 4.84 |
| Total Current Assets | 1,236.49 | 1,183.39 | 1,000.67 |
| Capital Lease Obligations | 34.4 | 25.14 | 17.16 |
| Accumulated Depreciation Total | Not available | -543.55 | -334.01 |
| Accrued Expenses | Not available | 11.08 | 9.58 |
| Other Equity Total | Not available | 40.92 | 53.29 |
| Prepaid Expenses | Not available | 14.5 | 8.27 |
| Additional Paid-In Capital | Not available | 711.41 | 490.22 |
| Cash | Not available | 68.25 | 80.25 |
| Property/Plant/Equipment Total-Gross | Not available | 1,187.46 | 1,090.77 |
| Notes Payable/Short Term Debt | Not available | 271 | 233.46 |
| Unrealized Gain(Loss) | Not available | 0 | 44.91 |
Valuation and ratios
Growth
Debt 5Yr CAGR %5.54
Margins
Operating Margin 12m-0.16
Operating Margin 5y Avg6.6
Net Profit Margin 12m-2.11
Net Profit Margin 5y2.36
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio0.14
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk63.07
Recommendations
RatingBuy
Target High298
Target Low96.3
Target Mean2.5
Target Median87.5
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Asian Paints | INR 2,680 | 2.57 L | 58.09 | — |
| — | Solar Industries India | INR 18,880.05 | 1.71 L | 99.61 | — |
| — | Pidilite Industries | INR 1,574.3 | 1.60 L | 64.76 | — |
| — | SRF | INR 2,866.25 | 85,204.75 | 44.57 | — |
| — | Linde India | INR 6,895 | 58,803.47 | 110.53 | — |
Ownership
- Promoter
- 48.03%
- FII
- 0.91%
- MF
- 5.12%
- Other
- 45.94%
Events
- annual General MeetingAGM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsPreferential Issue of shares
- annual General MeetingPOM
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- rightsRights issue of equity shares of Re. 1/- in the ratio of 5:41 @ premium of Rs. 109/-.
- board MeetingsInter alia, to consider, discuss and decide various matters in connection with the Rights Issues.
- board MeetingsInter alia, to consider : 1. The revision of the quantum of the proposed Rights isue to an amount not exceeding Rs. 225 crores; and 2. Issue of any debt securities of the Company.
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Camlin Fine Sciences files BRSR for FY 2025-26 scanx.trade
Camlin Fine Sciences Reports ₹23.54 Cr Profit Amidst Revenue Growth and EBITDA Drop Whalesbook
Camlin Fine Sciences schedules 33rd AGM for August 11 scanx.trade
Camlin Fine Sciences Ltd is Rated Strong Sell MarketsMojo
Vinpai: Camlin Fine Sciences Holds 95.41% of Capital After Its Simplified Tender Offer, No Mandatory Squeeze-Out Idéal Investisseur
Camlin Fine Sciences Discloses Resignation of Senior R&D Executive The Globe and Mail
Business information
Camlin Fine Sciences Limited is an India-based specialty chemicals company, which is engaged in the research, development, manufacturing and marketing of specialty chemicals, ingredients, and additive blends. The Company's products portfolio is categorized into shelf-life solutions, performance chemicals, aroma ingredients, and health and wellness. Its products include catechol, tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), Ascorbyl Palmitate (ASP), 4-Tertiary Butyl Catechol, Xtendra, Guaiacol, Para DiMethoxy Benzene, NaSure, Hydroquinone, and Veratrole. Its aroma ingredients mainly include Vanillin, Ethyl Vanillin, and Natural Vanillin. The Company's products are used in varied industries, such as human food, animal feed, pet food, agrochemicals, petrochemicals, pharmaceuticals, nutraceuticals, flavors and fragrances, and health care. Its brands include Ezential, Nasure, adorr, Dinamics, Xtendra, and Biosus.
- Industry
- Chemical Manufacturing
- Sector
- Chemical Manufacturing
- Website
- Not available
- Address
- Not available
- NSE Code
- CAMLINFINE
- BSE Code
- 532834
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Camlin Fine Sciences?
Camlin Fine Sciences has the symbol CAMLINFINE and ISIN - INE052I01032.
What is the current price of Camlin Fine Sciences?
Camlin Fine Sciences is currently trading at INR 122.14.
What are the year high and year low of Camlin Fine Sciences?
Camlin Fine Sciences has a year high of INR 298.00 and a year low of INR 96.30.
What is the market capitalization of Camlin Fine Sciences?
Camlin Fine Sciences has a market capitalization of INR 2,388.80 crore.
What is the P/E ratio of Camlin Fine Sciences?
Camlin Fine Sciences has a P/E ratio of NA.
What is the dividend yield of Camlin Fine Sciences?
Camlin Fine Sciences has a dividend yield of 0.00%.
How is the financial performance of Camlin Fine Sciences based on revenue, net income, and EPS?
Camlin Fine Sciences has revenue of INR 17,233.08 crore, net income of INR -274.47 crore, and EPS of INR -1.28.
What is the book value of Camlin Fine Sciences?
Camlin Fine Sciences has a book value of INR 40.53.
What is the debt-to-equity ratio of Camlin Fine Sciences?
Camlin Fine Sciences has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Camlin Fine Sciences?
Camlin Fine Sciences has a price-to-book ratio of 3.01 and a price-to-sales ratio of 0.14.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
